Kappos L - Search Results

1

Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.

Cagol A, Benkert P, Melie-Garcia L, Schaedelin SA, Leber S, Tsagkas C, Barakovic M, Galbusera R, Lu PJ, Weigel M, Ruberte E, Radue EW, Yaldizli Ö, Oechtering J, Lorscheider J, D'Souza M, Fischer-Barnicol B, Müller S, Achtnichts L, Vehoff J, Disanto G, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb JM, Remonda L, Wagner F, Vargas MI, Du Pasquier RA, Lalive PH, Pravatà E, Weber J, Cattin PC, Absinta M, Gobbi C, Leppert D, Kappos L, Kuhle J, Granziera C. Cagol A, et al. Among authors: kappos l. Neurology. 2024 Jan 9;102(1):e207768. doi: 10.1212/WNL.0000000000207768. Epub 2023 Dec 13. Neurology. 2024. PMID: 38165377 Free PMC article.

2

Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal-appearing white matter.

Roser W, Hagberg G, Mader I, Brunnschweiler H, Radue EW, Seelig J, Kappos L. Roser W, et al. Among authors: kappos l. Magn Reson Med. 1995 Jun;33(6):811-7. doi: 10.1002/mrm.1910330611. Magn Reson Med. 1995. PMID: 7651118

3

Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis.

Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S, Miller KM, Hauser SL, Kappos L. Leppert D, et al. Among authors: kappos l. Brain. 1998 Dec;121 ( Pt 12):2327-34. doi: 10.1093/brain/121.12.2327. Brain. 1998. PMID: 9874483

4

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HL, Gasperini C, Filippi M. Kappos L, et al. Lancet. 1999 Mar 20;353(9157):964-9. doi: 10.1016/s0140-6736(98)03053-0. Lancet. 1999. PMID: 10459905

5

Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study.

Mader I, Roser W, Kappos L, Hagberg G, Seelig J, Radue EW, Steinbrich W. Mader I, et al. Among authors: kappos l. AJNR Am J Neuroradiol. 2000 Aug;21(7):1220-7. AJNR Am J Neuroradiol. 2000. PMID: 10954272 Free PMC article. Clinical Trial.

6

Interleukin 15 stimulates production of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by human peripheral blood mononuclear cells.

Constantinescu CS, Grygar C, Kappos L, Leppert D. Constantinescu CS, et al. Among authors: kappos l. Cytokine. 2001 Feb 21;13(4):244-7. doi: 10.1006/cyto.2000.0818. Cytokine. 2001. PMID: 11237433

7

The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis.

Lindberg RL, De Groot CJ, Montagne L, Freitag P, van der Valk P, Kappos L, Leppert D. Lindberg RL, et al. Among authors: kappos l. Brain. 2001 Sep;124(Pt 9):1743-53. doi: 10.1093/brain/124.9.1743. Brain. 2001. PMID: 11522577

8

Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis.

Leppert D, Lindberg RL, Kappos L, Leib SL. Leppert D, et al. Among authors: kappos l. Brain Res Brain Res Rev. 2001 Oct;36(2-3):249-57. doi: 10.1016/s0165-0173(01)00101-1. Brain Res Brain Res Rev. 2001. PMID: 11690622 Review.

9

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

Freeman JA, Thompson AJ, Fitzpatrick R, Hutchinson M, Miltenburger C, Beckmann K, Dahlke F, Kappos L, Polman C, Pozzilli C; European Study Group on Interferon-beta1b in Secondary Progressive MS. Freeman JA, et al. Among authors: kappos l. Neurology. 2001 Nov 27;57(10):1870-5. doi: 10.1212/wnl.57.10.1870. Neurology. 2001. PMID: 11723278 Clinical Trial.

10

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.

Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F; European Study Group in Interferon beta-1b in Secondary-Progressive MS. Kappos L, et al. Neurology. 2001 Dec 11;57(11):1969-75. doi: 10.1212/wnl.57.11.1969. Neurology. 2001. PMID: 11739811 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

794 results

Search Page